Insider · CIK 0001778713

Cadavid Diego

Reports to the SEC for 2 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001778713

Forms 4 and 5

Insider transactions

37 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-03-01	XFORX4 Pharmaceuticals, IncA Award	Chief Medical Officer	AAward	+97K sh	—	—	104,107
2022-02-11	XFORX4 Pharmaceuticals, IncS Sale	Chief Medical Officer	SSale	−928 sh	—	—	7,107
2021-03-24	XFORX4 Pharmaceuticals, IncA Award	Chief Medical Officer	AAward	+8,035 sh	—	—	8,035
2020-12-31	XFORX4 Pharmaceuticals, Inc · Stock Option (right to buy)A Award	Chief Medical Officer	AAward	+122K sh	$6.43	+$781K	121,500
2020-07-01	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−1,071 sh	$18.30	−$19.6K	65,714
2020-06-25	FULCFulcrum Therapeutics, Inc.M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	+1,459 sh	$4.83	+$7,046.97	68,244
2020-06-25	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−1,459 sh	$22.00	−$32.1K	66,785
2020-06-25	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	−1,459 sh	—	—	12,277
2020-06-10	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−401 sh	$22.00	−$8,822	66,785
2020-06-10	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	−401 sh	—	—	13,736
2020-06-10	FULCFulcrum Therapeutics, Inc.M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	+401 sh	$4.83	+$1,936.83	67,186
2020-06-05	FULCFulcrum Therapeutics, Inc.M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	+451 sh	$4.83	+$2,178.33	67,236
2020-06-05	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	−451 sh	—	—	14,137
2020-06-05	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−451 sh	$20.18	−$9,100.774	66,785
2020-06-04	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−226 sh	$20.05	−$4,531.255	66,785
2020-06-04	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	−226 sh	—	—	14,588
2020-06-04	FULCFulcrum Therapeutics, Inc.M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	+226 sh	$4.83	+$1,091.58	67,011
2020-06-03	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−338 sh	$20.18	−$6,819.589	66,785
2020-06-03	FULCFulcrum Therapeutics, Inc.M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	+338 sh	$4.83	+$1,632.54	67,123
2020-06-03	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	−338 sh	—	—	14,814
2020-06-02	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	−45 sh	—	—	15,152
2020-06-02	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−45 sh	$20.00	−$900	66,785
2020-06-02	FULCFulcrum Therapeutics, Inc.M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	+45 sh	$4.83	+$217.35	66,830
2020-05-29	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−200 sh	$20.04	−$4,007	66,785
2020-05-29	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	−200 sh	—	—	15,197
2020-05-29	FULCFulcrum Therapeutics, Inc.M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	+200 sh	$4.83	+$966	66,985
2020-05-28	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	−600 sh	—	—	15,397
2020-05-28	FULCFulcrum Therapeutics, Inc.M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	+600 sh	$4.83	+$2,898	67,385
2020-05-28	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−600 sh	$20.00	−$12K	66,785
2020-05-12	FULCFulcrum Therapeutics, Inc.M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	+1,860 sh	$4.83	+$8,983.8	68,645
2020-05-12	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−1,860 sh	$18.00	−$33.5K	66,785
2020-05-12	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	SVP Clinical Development	MExercise/Conversion	−1,860 sh	—	—	15,997
2020-03-02	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−315 sh	$18.13	−$5,709.532	66,785
2020-03-02	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−1,828 sh	$17.26	−$31.5K	67,100
2020-02-03	FULCFulcrum Therapeutics, Inc.S Sale	SVP Clinical Development	SSale	−2,143 sh	$17.33	−$37.1K	68,928
2020-01-23	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)A Award	SVP Clinical Development	AAward	+55.4K sh	—	—	55,440
2019-07-18	FULCFulcrum Therapeutics, Inc. · Stock Option (right to buy)A Award	SVP Clinical Development	AAward	+12.8K sh	—	—	12,784

Recent filings

Accepted (ET)
Mar 14
Cadavid Diego0001628280-22-004495
SEC(opens sec.gov)
Feb 144
Cadavid Diego0001628280-22-002505
SEC(opens sec.gov)
Mar 254
Cadavid Diego0001628280-21-005661
SEC(opens sec.gov)
Jan 64
Cadavid Diego0001628280-21-000147
SEC(opens sec.gov)
Jul 24
Cadavid Diego0000899243-20-018278
SEC(opens sec.gov)
Jun 264
Cadavid Diego0000899243-20-017761
SEC(opens sec.gov)
Jun 124
Cadavid Diego0000899243-20-016382
SEC(opens sec.gov)
Jun 84
Cadavid Diego0000899243-20-015623
SEC(opens sec.gov)
Jun 44
Cadavid Diego0000899243-20-015245
SEC(opens sec.gov)

Companies

Address

C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET

CAMBRIDGE, MA, 02139